Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Allemagne)

Index « Auteurs » - entrée « Andrzej Mackiewicz »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Andrzej M. Jagodzinski < Andrzej Mackiewicz < Andrzej Paj K  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 4.
Ident.Authors (with country if any)Title
000048 (2017) Dirk Schadendorf [Allemagne] ; Georgina V. Long [Australie] ; Daniil Stroiakovski [Russie] ; Boguslawa Karaszewska [Pologne] ; Axel Hauschild [Allemagne] ; Evgeny Levchenko [Russie] ; Vanna Chiarion-Sileni [Italie] ; Jacob Schachter [Israël] ; Claus Garbe [Allemagne] ; Caroline Dutriaux [France] ; Helen Gogas [Grèce] ; Mario Mandalà [Italie] ; John B A G. Haanen [Pays-Bas] ; Céleste Lebbé [France] ; Andrzej Mackiewicz [Pologne] ; Piotr Rutkowski [Pologne] ; Jean-Jacques Grob [France] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Michael A. Davies [États-Unis] ; Ying Zhang [États-Unis] ; Mathilde Kaper [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Jeffrey J. Legos [États-Unis] ; Keith T. Flaherty [États-Unis] ; Caroline Robert [France]Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
000261 (2017) Paolo A. Ascierto [Italie] ; Michele Del Vecchio [Italie] ; Caroline Robert [France] ; Andrzej Mackiewicz [Pologne] ; Vanna Chiarion-Sileni [Italie] ; Ana Arance [Espagne] ; Céleste Lebbé [France] ; Lars Bastholt [Danemark] ; Omid Hamid [États-Unis] ; Piotr Rutkowski [Pologne] ; Catriona Mcneil [Australie] ; Claus Garbe [Allemagne] ; Carmen Loquai [Allemagne] ; Brigitte Dreno [France] ; Luc Thomas [France] ; Jean-Jacques Grob [France] ; Gabriella Liszkay [Hongrie] ; Marta Nyakas [Norvège] ; Ralf Gutzmer [Allemagne] ; Joanna Pikiel [Pologne] ; Florent Grange [France] ; Christoph Hoeller [Autriche] ; Virginia Ferraresi [Italie] ; Michael Smylie [Canada] ; Dirk Schadendorf [Allemagne] ; Laurent Mortier [France] ; Inge Marie Svane [Danemark] ; Delphine Hennicken [États-Unis] ; Anila Qureshi [États-Unis] ; Michele Maio [Italie]Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
000D76 (2015) Jean Jacques Grob [France] ; Mayur M. Amonkar [États-Unis] ; Boguslawa Karaszewska [Pologne] ; Jacob Schachter [Israël] ; Reinhard Dummer [Suisse] ; Andrzej Mackiewicz [Pologne] ; Daniil Stroyakovskiy [Russie] ; Kamil Drucis [Pologne] ; Florent Grange [France] ; Vanna Chiarion-Sileni [Italie] ; Piotr Rutkowski [Pologne] ; Mikhail Lichinitser [Russie] ; Evgeny Levchenko [Russie] ; Pascal Wolter [Belgique] ; Axel Hauschild [Allemagne] ; Georgina V. Long [Australie] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Keith Flaherty [États-Unis] ; Peng Sun [États-Unis] ; Jeffrey J. Legos [États-Unis] ; Diane Opatt Mcdowell [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Dirk Schadendorf [Allemagne] ; Caroline Robert [France]Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
000E13 (2015) Dalil Hannani [France] ; Marie Vétizou [France] ; David Enot [France] ; Sylvie Rusakiewicz [France] ; Nathalie Chaput [France] ; David Klatzmann [France] ; Melanie Desbois [France] ; Nicolas Jacquelot [France] ; Nadège Vimond [France] ; Salem Chouaib [France] ; Christine Mateus [France] ; James P. Allison [États-Unis] ; Antoni Ribas [États-Unis] ; Jedd D. Wolchok [États-Unis] ; Jianda Yuan [États-Unis] ; Philip Wong [États-Unis] ; Michael Postow [États-Unis] ; Andrzej Mackiewicz [Pologne] ; Jacek Mackiewicz [Pologne] ; Dirk Schadendorff [Allemagne] ; Dirk Jaeger [Allemagne] ; Alan J. Korman [États-Unis] ; Keith Bahjat [États-Unis] ; Michele Maio [Italie] ; Luana Calabro [Italie] ; Michele Wl Teng [Australie] ; Mark J. Smyth [Australie] ; Alexander Eggermont [France] ; Caroline Robert [France] ; Guido Kroemer [France] ; Laurence Zitvogel [France]Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

List of associated KwdEn.i

Nombre de
documents
Descripteur
4Humans
3Aged
3Female
3Male
3Melanoma (drug therapy)
3Middle Aged
2Adult
2Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
2Imidazoles (administration & dosage)
2Intention to Treat Analysis
2Melanoma (mortality)
2Melanoma (pathology)
2Melanoma (secondary)
2Oximes (administration & dosage)
2Protein Kinase Inhibitors (therapeutic use)
2Pyridones (administration & dosage)
2Pyrimidinones (administration & dosage)
2Risk Factors
2Treatment Outcome
1Administration, Oral
1Adolescent
1Aged, 80 and over
1Alanine Transaminase (blood)
1Animals
1Antibodies, Monoclonal (administration & dosage)
1Antibodies, Monoclonal (adverse effects)
1Antibodies, Monoclonal (pharmacology)
1Antibodies, Monoclonal (therapeutic use)
1Antineoplastic Agents (administration & dosage)
1Antineoplastic Agents (adverse effects)
1Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
1Antineoplastic Combined Chemotherapy Protocols (adverse effects)
1Biomarkers, Tumor (genetics)
1CD4-Positive T-Lymphocytes (immunology)
1CD4-Positive T-Lymphocytes (metabolism)
1CTLA-4 Antigen (immunology)
1CTLA-4 Antigen (metabolism)
1Cohort Studies
1Colitis (chemically induced)
1DNA Mutational Analysis
1Diarrhea (chemically induced)
1Disease Models, Animal
1Disease Progression
1Disease-Free Survival
1Double-Blind Method
1Drug Administration Schedule
1Follow-Up Studies
1Genetic Predisposition to Disease
1Hypophysitis (chemically induced)
1Imidazoles (adverse effects)
1Imidazoles (therapeutic use)
1Immunotherapy
1Indoles (administration & dosage)
1Indoles (adverse effects)
1Indoles (therapeutic use)
1Interleukin-2 Receptor alpha Subunit (blood)
1Interleukin-2 Receptor alpha Subunit (immunology)
1L-Lactate Dehydrogenase (metabolism)
1MAP Kinase Kinase Kinases (antagonists & inhibitors)
1MAP Kinase Kinase Kinases (metabolism)
1Melanoma (genetics)
1Melanoma (metabolism)
1Melanoma (therapy)
1Mice
1Mice, Inbred C57BL
1Mutation
1Neoplasm Metastasis (pathology)
1Oximes (adverse effects)
1Oximes (therapeutic use)
1Phenotype
1Predictive Value of Tests
1Prognosis
1Prospective Studies
1Protein Kinase Inhibitors (administration & dosage)
1Protein Kinase Inhibitors (adverse effects)
1Proto-Oncogene Proteins B-raf (antagonists & inhibitors)
1Proto-Oncogene Proteins B-raf (genetics)
1Pyridones (adverse effects)
1Pyridones (therapeutic use)
1Pyrimidinones (adverse effects)
1Pyrimidinones (therapeutic use)
1Quality of Life
1Receptors, Interleukin-2 (genetics)
1Receptors, Interleukin-2 (immunology)
1Receptors, Interleukin-2 (metabolism)
1Recombinant Proteins (biosynthesis)
1Recombinant Proteins (genetics)
1Recombinant Proteins (pharmacology)
1Skin Neoplasms (drug therapy)
1Skin Neoplasms (genetics)
1Skin Neoplasms (mortality)
1Skin Neoplasms (pathology)
1Sulfonamides (administration & dosage)
1Sulfonamides (adverse effects)
1Sulfonamides (therapeutic use)
1Surveys and Questionnaires
1Survival Analysis
1Survival Rate
1T-Lymphocytes, Regulatory (immunology)
1Time Factors

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Andrzej Mackiewicz" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i  \
                -Sk "Andrzej Mackiewicz" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Allemagne
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Andrzej Mackiewicz
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024